載入...
Nano-targeted Delivery of Rad6/Translesion Synthesis Inhibitor for Triple Negative Breast Cancer Therapy
The triple negative breast cancer (TNBC) subtype regardless of their BRCA1 status has the poorest outcome compared to other breast cancer subtypes and currently there are no approved targeted therapies for TNBC. We have previously demonstrated the importance of Rad6-mediated translesion synthesis pa...
Na minha lista:
| 發表在: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6279467/ https://ncbi.nlm.nih.gov/pubmed/30242094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0364 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|